Amgen 386 for Recurrent Glioblastoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Dana-Farber Cancer Institute
Sponsor:
Collaborator:
Amgen
Information provided by (Responsible Party):
David Reardon, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01290263
First received: January 9, 2011
Last updated: July 28, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)